PRKCA and cancer: PTS treatment facilitates DNMT3B recruitment to regions with diminished OCT1 binding, resulting in hypermethylation of the protein kinase C alpha (PRKCA) promoter and the DNA-damage-inducible transcript 2 (DANT2) and troponin T2 (TNNT2) enhancers, thereby inhibiting cancer cell growth [199].